Robert Renninger - 24 Dec 2025 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role: Chief Financial Officer
Signature: /s/ Mark Worthington, Attorney-in-Fact on behalf of Robert Renninger
Issuer symbol: ATHA
Transactions as of: 24 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 29 Dec 2025, 16:19:08 UTC
Previous filing: 02 Jul 2025
Next filing: 05 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Renninger Robert	Chief Financial Officer	C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL	/s/ Mark Worthington, Attorney-in-Fact on behalf of Robert Renninger	29 Dec 2025	0002037968

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATHA	Stock Option (Right to Buy)	Award	$0	+34,358		$0.000000	34,358	24 Dec 2025	Common Stock	34,358	$4.07	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F2	On September 24, 2025, the reporting person was granted an option to purchase 34,358 shares of common stock. The option was scheduled to vest only upon satisfaction of both a milestone requirement (the "Milestone Requirement") and a service-based requirement (the "Service-Based Requirement"). The Milestone Requirement was satisfied on December 23, 2025. The Service-Based Requirement will be satisfied as to 50% of the total number of shares granted under the option on December 23, 2026 and as to 1/36th of the remaining 50% on the 23rd day of each month thereafter, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.

Content

The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

On September 24, 2025, the reporting person was granted an option to purchase 34,358 shares of common stock. The option was scheduled to vest only upon satisfaction of both a milestone requirement (the "Milestone Requirement") and a service-based requirement (the "Service-Based Requirement"). The Milestone Requirement was satisfied on December 23, 2025. The Service-Based Requirement will be satisfied as to 50% of the total number of shares granted under the option on December 23, 2026 and as to 1/36th of the remaining 50% on the 23rd day of each month thereafter, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.